Pharmagreen Biotech Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Peter Wojcik
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.8yrs |
| CEO ownership | 5.3% |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
No updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$404k |
| Mar 31 2024 | n/a | n/a | -US$524k |
| Dec 31 2023 | n/a | n/a | -US$674k |
| Sep 30 2023 | n/a | n/a | -US$569k |
| Jun 30 2023 | n/a | n/a | -US$501k |
| Mar 31 2023 | n/a | n/a | -US$86k |
| Dec 31 2022 | n/a | n/a | -US$934k |
| Sep 30 2022 | US$94k | US$94k | -US$875k |
| Jun 30 2022 | n/a | n/a | -US$2m |
| Mar 31 2022 | n/a | n/a | -US$2m |
| Dec 31 2021 | n/a | n/a | -US$4m |
| Sep 30 2021 | US$95k | US$95k | -US$5m |
| Jun 30 2021 | n/a | n/a | -US$5m |
| Mar 31 2021 | n/a | n/a | -US$6m |
| Dec 31 2020 | n/a | n/a | -US$3m |
| Sep 30 2020 | US$93k | US$93k | -US$2m |
| Jun 30 2020 | n/a | n/a | -US$2m |
| Mar 31 2020 | n/a | n/a | -US$491k |
| Dec 31 2019 | n/a | n/a | -US$581k |
| Sep 30 2019 | US$90k | US$90k | -US$768k |
| Jun 30 2019 | n/a | n/a | -US$413k |
| Mar 31 2019 | n/a | n/a | -US$1m |
| Dec 31 2018 | n/a | n/a | -US$1m |
| Sep 30 2018 | US$102k | n/a | -US$742k |
Compensation vs Market: Insufficient data to establish whether Peter's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
CEO
Peter Wojcik (52 yo)
6.8yrs
Tenure
US$93,964
Compensation
Mr. Peter Wojcik, B.A. Adv., serves as Chief Executive Officer and Director at Pharmagreen Biotech Inc., since February 2, 2018 and serves as its President, Secretary and Treasurer since February 21, 2018....